Redefining Cancer Treatment: Interview with Dr. Charles Link on Sync-T and the Future of Immunotherapy

Join host Bree Clare as she speaks with Dr. Charles Link, a pioneering oncologist and immunotherapy researcher who's spent decades reshaping the landscape of cancer medicine.  In this episode, Dr. Link breaks down SYNC-T, a revolutionary in-situ immunotherapy platform that's redefining treatment possibilities for hard-to-treat cancers. We'll explore how this multi-target immunotherapy works to educate the immune system to recognize and attack cancer and learn about an exciting Phase 2 clinical trial now enrolling patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Whether you're a patient, caregiver, researcher, or simply seeking hope and inspiration at the frontiers of medicine, this conversation offers a rare glimpse into decades of clinical innovation and the relentless pursuit of better outcomes for cancer patients everywhere. Listen now for hope, science, and the future of cancer treatment. And to learn more about Syncromune please visit: Syncromune — Now Enrolling LEGION-100 Trial for mCRPC or the LEGION-100 trial at LEGION-100 Clinical Trial | mCRPC Prostate Cancer | Syncromune